Metsera (NASDAQ:MTSR) Trading Down 4.8% – Here’s Why

Metsera, Inc. (NASDAQ:MTSR)’s stock price fell 4.8% during trading on Tuesday . The stock traded as low as $25.62 and last traded at $25.91. 125,837 shares traded hands during trading, a decline of 81% from the average session volume of 650,358 shares. The stock had previously closed at $27.22.

Analyst Upgrades and Downgrades

MTSR has been the topic of several recent analyst reports. Cantor Fitzgerald assumed coverage on Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Guggenheim began coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Finally, Bank of America initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target on the stock.

Metsera Stock Down 6.4 %

Metsera (NASDAQ:MTSR) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.